Antares Pharma (NASDAQ:ATRS) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday.
A number of other analysts have also recently issued reports on ATRS. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Antares Pharma in a research report on Sunday, September 10th. Finally, ValuEngine cut Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $3.84.
Shares of Antares Pharma (NASDAQ:ATRS) opened at $2.05 on Friday. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09. The stock has a market capitalization of $316.48, a P/E ratio of -18.64 and a beta of 0.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89.
In other news, Director Thomas J. Garrity sold 30,000 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Advantage Inc. bought a new position in shares of Antares Pharma during the third quarter worth approximately $110,000. Alliancebernstein L.P. bought a new position in shares of Antares Pharma during the second quarter worth approximately $119,000. Legal & General Group Plc bought a new position in shares of Antares Pharma during the second quarter worth approximately $120,000. MML Investors Services LLC increased its stake in shares of Antares Pharma by 228.2% during the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 30,000 shares during the period. Finally, First Eagle Investment Management LLC increased its stake in shares of Antares Pharma by 150.0% during the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock worth $162,000 after purchasing an additional 30,000 shares during the period. Institutional investors own 34.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/24/bidaskclub-upgrades-antares-pharma-atrs-to-buy.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.